Talazoparib is a PARP inhibitor used for the treatment of certain solid tumors such as breast cancer.The medication risk is significantly increased in some populations, so contraindications and precautions must be strictly understood.

1.Patients with severe myelosuppression

1.Risk mechanism

Talazoparib can inhibit bone marrow hematopoiesis, leading to decreased blood cell counts.

In patients with existing severe myelosuppression, the medication may further increase the risk of anemia, infection, and bleeding.

2.Contraindications and monitoring

A complete blood count must be checked before treatment to confirm baseline levels.

If severe myelosuppression is present, the medication should be contraindicated or temporarily withheld.

During treatment, hemoglobin, neutrophil, and platelet counts should be monitored regularly.

If abnormalities occur, the dose should be adjusted or the medication paused promptly, and supportive treatment should be given when necessary.

2.Pregnant women

1.Fetal risk

Based on its mechanism of action, talazoparib has teratogenic and embryolethal risks.

Use in pregnant women may cause harm to the fetus.

2.Medication recommendations

Talazoparib is contraindicated in pregnant women.

Women of childbearing potential should undergo pregnancy testing before treatment.

Effective contraception should be used during treatment and for a period after discontinuation.

If pregnancy occurs during treatment, the doctor should be informed immediately and the risk should be assessed.

3.Breastfeeding patients

1.Risk of milk secretion

It is not yet known whether talazoparib is secreted into human milk.

Animal studies suggest that the drug may enter breast milk and cause potential harm to the infant.

2.Medication recommendations

Talazoparib is contraindicated in breastfeeding women.

Breastfeeding should be stopped during treatment and for a period after the last dose.

If medication is needed, alternative feeding methods should be discussed with the doctor.

4.General recommendations

Before medication, comprehensively assess bone marrow function, pregnancy status, and breastfeeding status.

During treatment, closely monitor blood counts and adverse reactions.

Women of childbearing potential should strictly use contraception, and breastfeeding women should stop breastfeeding.

Seek medical attention promptly if severe adverse reactions occur, and do not adjust the dose on your own.